NDA Withdrawn, But Genta's Genasense Work To Continue

Genta Inc.'s decision to reduce its work force as a way of focusing on the melanoma therapy Genasense, combined with the simultaneous move to withdraw the new drug application for that lead product, "might be confusing from an external perspective," conceded Joy Schmitt, spokeswoman for the company. (BioWorld Today)